



**INDIAN PHARMACOPOEIA COMMISSION**  
**National Coordination Centre- Pharmacovigilance Programme of India (PvPI)**

MINISTRY OF HEALTH & FAMILY WELFARE, GOVERNMENT OF INDIA  
SECTOR-23, RAJ NAGAR, GHAZIABAD- 201 002.

Tel No: 0120- 2783392, 2783400, 2783401 Fax: 0120-2783311  
e-mail: [pvpi@ipcindia.net](mailto:pvpi@ipcindia.net); [ipclab@vsnl.net](mailto:ipclab@vsnl.net), Web: [www.ipc.gov.in](http://www.ipc.gov.in)

## **Drug Alert**

The preliminary analysis of SUSARs from the PvPI database reveals that the following drugs are associated with the risks as given below.

**Table**

S.No	Suspected Drugs	Indication	Adverse Reactions
1	Phenytoin	Generalized tonic-clonic seizures; partial seizures; status epilepticus	Angioedema
2	Phenytoin	Generalized tonic-clonic seizures; partial seizures; status epilepticus	Osteoporosis
3	Nicorandil	Angina Pectoris, Vasodialator	Risk of ulcer complication
4	Olanzapine	Schizophrenia, acute mania episodes in bipolar disorder	Hyponatraemia
5	Crizotinib	Locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)	Risk of cardiac failure

Health care professionals, Patients/Consumers are advised to closely monitor the possibility of the above adverse events while prescribing/consuming above suspected drugs and report to the NCC-PvPI either by filling of Suspected Adverse Drug Reactions Reporting Form/ Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>) or by PvPI Helpline no. 18001803024.

*“Let us join hands with PvPI to ensure patients safety”*

**ADR Reporting Help line (Toll Free): 1800-180-3024**